MAWAG
TERN

Mid-American Wealth Advisory Group’s Terns Pharmaceuticals TERN Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-301
Closed -$1.12K – 292
2025
Q2 		$1.12K Buy
+301
New +$940 ﹤0.01% 287

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Mid-American Wealth Advisory Group's TERN Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Terns Pharmaceuticals (TERN) in Q3 2025, closing a stake of 301 shares — an estimated $1.12K sold.

Mid-American Wealth Advisory Group first reported a position in TERN in Q2 2025 and held it in 1 quarter. The position peaked at $1.12K in Q2 2025. 141 funds tracked by Wall St. Rank hold TERN as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Terns Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 301 Terns Pharmaceuticals shares in Q3 2025, an estimated $1.12K.
  • Mid-American Wealth Advisory Group first reported a position in Terns Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Terns Pharmaceuticals position peaked at $1.12K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.